 Connection
Bradley Corr to Endometrial Neoplasms
This is a "connection" page, showing publications Bradley Corr has written about Endometrial Neoplasms.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
6.024 |
|
|
|
-
Corr BR, Haggerty A, Gysler SM, Taylor S, Behbakht K, Alldredge J, Lefkowits C, Brubaker LW, Bouts C, Babayan LM, Martin LP, Costello J, Bitler BG, Hu J, Guntupalli SR. A phase II, randomized, double-blind study of the use of rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancer. Gynecol Oncol. 2025 Sep; 200:58-67.
Score: 0.801
-
Corr BR, Erickson BK, Barber EL, Fisher CM, Slomovitz B. Advances in the management of endometrial cancer. BMJ. 2025 Mar 05; 388:e080978.
Score: 0.780
-
Haag JG, Wolsky RJ, Moroney MR, Sheren J, Sheeder J, Bitler BG, Corr BR. Clinicopathologic Evaluation of CTNNB1 Mutations in High-Intermediate Risk Endometrial Endometrioid Carcinoma. Int J Gynecol Pathol. 2023 Jan 01; 42(1):43-53.
Score: 0.635
-
Moroney MR, Woodruff E, Qamar L, Bradford AP, Wolsky R, Bitler BG, Corr BR. Inhibiting Wnt/beta-catenin in CTNNB1-mutated endometrial cancer. Mol Carcinog. 2021 08; 60(8):511-523.
Score: 0.600
-
Moroney MR, Davies KD, Wilberger AC, Sheeder J, Post MD, Berning AA, Fisher C, Lefkowits C, Guntupalli SR, Behbakht K, Corr BR. Molecular markers in recurrent stage I, grade 1 endometrioid endometrial cancers. Gynecol Oncol. 2019 06; 153(3):517-520.
Score: 0.516
-
Corr BR, Carrubba A, Sheeder J, Cheng G, Guntupalli SR. Histopathology Discrepancy of Preoperative Endometrial Sampling and Final Specimen: How Does This Influence Selective Lymph Node Dissection? Int J Gynecol Cancer. 2017 02; 27(2):297-301.
Score: 0.445
-
Lee SS, Secord AA, Friedman S, Hade EM, Smitherman C, Bisht N, Borden L, Jackson AL, Backes F, Thaker P, Arend R, Wright JD, Corr B, Ko E, Konecny G, Podwika S, Bae-Jump V, Hacker KE, Pothuri B. Molecular characteristics by race and ethnicity of patients with high tumor mutational burden, high microsatellite instability, and mismatch repair deficiency: Real-world data from the multi-institutional Endometrial cancer Molecularly Targeted Therapy Consortium (ECMT2). Gynecol Oncol. 2025 Aug; 199:152-158.
Score: 0.200
-
Gonzalez Bosquet J, Polio A, George E, Tarhini AA, Cosgrove CM, Huang MS, Corr B, Leiser AL, Salhia B, Darcy K, Tarney CM, Dood RL, Dockery LE, Edge SB, Cavnar MJ, Landrum L, Rounbehler RJ, Churchman M, Wagner VM. Training, Validating, and Testing Machine Learning Prediction Models for Endometrial Cancer Recurrence. JCO Precis Oncol. 2025 May; 9:e2400859.
Score: 0.197
-
Secord AA, Bae-Jump V, Backes F, Thaker P, Gehrig PA, Previs RA, Borden L, Thomas SM, Jackson A, Konecny GE, Duska LR, Arend R, Wright J, Corr B, Maxwell GL, Cosgrove CM, Mullen MM, Washington C, Herzog TJ, Cohen J, Hou J, Gaillard S, Fader AN, Berchuck A, Pothuri B. Genomic alterations, molecularly targeted therapy, and survival: a real-world Endometrial Cancer Molecularly Targeted Therapy Consortium cohort study. Int J Gynecol Cancer. 2025 May; 35(5):101758.
Score: 0.196
-
Eskander RN, Lee JY, Mirza MR, Lorusso D, MacKay H, Ray-Coquard I, Oaknin A, Gonzalez-Martin A, Hasegawa K, Corr BR, Wu X, Leary A, Hu T, Dutta L, Okpara CE, McKenzie J, Makker V. Randomized study evaluating optimal dose, efficacy, and safety of E7386 plus lenvatinib versus treatment of physician's choice in advanced/recurrent endometrial carcinoma previously treated with platinum-based chemotherapy and immune checkpoint inhibitors. Int J Gynecol Cancer. 2025 Sep; 35(9):101812.
Score: 0.196
-
Haight PJ, Sanchez M, Thomas SM, Smitherman C, Cosgrove C, Bae-Jump V, Crafton S, Hacker K, Ko E, Krivak T, Lara O, Moore K, Mullen MM, Pothuri B, Thaker PH, Washington C, Arend R, Corr B, Duska L, Jackson A, Konecny GE, Wright J, Secord A, Backes F. Platinum-free interval and response to platinum retreatment or lenvatinib/pembrolizumab in patients with recurrent endometrial cancer: A real-world endometrial cancer molecularly targeted therapy consortium cohort study. Gynecol Oncol. 2025 Mar; 194:98-104.
Score: 0.195
-
Clements A, Enserro D, Strickland KC, Previs R, Matei D, Mutch D, Powell M, Klopp A, Miller DS, Small W, DiSilvestro P, Spirtos N, Cosgrove C, Sfakianos G, Liu JR, Vargas R, Shahin M, Corr B, Dessources K, Ueland F, Warshal D, Gillen J, Secord AA. Molecular classification of endometrial cancers (EC) and association with relapse-free survival (RFS) and overall survival (OS) outcomes: Ancillary analysis of GOG-0258. Gynecol Oncol. 2025 Feb; 193:119-129.
Score: 0.194
-
Santin AD, Corr BR, Spira A, Willmott L, Butrynski J, Tse KY, Patel J, Mekan S, Wu T, Lin KW, Kuo P, Dumbrava EE. Efficacy and Safety of Sacituzumab Govitecan in Patients With Advanced Solid Tumors (TROPiCS-03): Analysis in Patients With Advanced Endometrial Cancer. J Clin Oncol. 2024 Oct 10; 42(29):3421-3429.
Score: 0.187
-
Chambers L, Haight P, Chalif J, Mehra Y, Spakowicz D, Backes FJ, Cosgrove CM, O'Malley DM, Vargas R, Corr BR, Bae-Jump VL, Arend RC. Bridging the Gap from Bench to Bedside: A Call for In Vivo Preclinical Models to Advance Endometrial Cancer and Cervical Cancer Immuno-oncology Research. Clin Cancer Res. 2024 Jul 15; 30(14):2905-2909.
Score: 0.187
-
Davies KD, Smith LP, Guimaraes-Young A, Corr BR, Fisher CM, Guntupalli SR, Berning AA, Post MD, Pino D, Aisner DL, Wolsky RJ. Prospective Clinical Prognostication of Endometrial Carcinomas Based on Next-Generation Sequencing and Immunohistochemistry-Real-World Implementation and Results at a Tertiary Care Center. Int J Gynecol Pathol. 2024 Jul 01; 43(4):335-348.
Score: 0.177
-
Whelan K, Dillon M, Strickland KC, Pothuri B, Bae-Jump V, Borden LE, Thaker PH, Haight P, Arend RC, Ko E, Jackson AL, Corr BR, Ayoola-Adeola M, Wright JD, Podwika S, Smitherman C, Thomas S, Lightfoot M, Newton M, Washington C, Mullen M, Cosgrove C, Harsono AAH, Powell K, Herzog TJ, Salani R, Alvarez Secord A. TP53 mutation and abnormal p53 expression in endometrial cancer: Associations with race and outcomes. Gynecol Oncol. 2023 11; 178:44-53.
Score: 0.176
-
McMellen A, Woodruff ER, Corr BR, Bitler BG, Moroney MR. Wnt Signaling in Gynecologic Malignancies. Int J Mol Sci. 2020 Jun 16; 21(12).
Score: 0.141
-
Carrubba AR, Corr BR, Sheeder J, Guntupalli SR. Evaluation of Preoperative Chest Imaging in Low-Risk Endometrial Cancer Patients. Int J Gynecol Cancer. 2016 Feb; 26(2):348-53.
Score: 0.104
-
Doo DW, Guntupalli SR, Corr BR, Sheeder J, Davidson SA, Behbakht K, Jarrett MJ, Guy MS. Comparative Surgical Outcomes for Endometrial Cancer Patients 65 Years Old or Older Staged With Robotics or Laparotomy. Ann Surg Oncol. 2015 Oct; 22(11):3687-94.
Score: 0.097
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|